We are delighted to announce that the journal impact factor (JIF) of Acta Cytologica was finally released in June 2020, after 6 years of interruption. The new JIF of 2019 is 1.226.

Those of you who would like a reminder of the technical details of how the JIF is calculated, the reasons given for the removal of Acta Cytologica’s JIF in 2014, and our subsequent appeals in 2017, 2018, and 2019, we would like to refer to the following Editorial and Publisher’s Notes [1-3], as it is not feasible to reiterate the whole intriguing story in this short Editorial.

The main purpose of this Editorial is to extend deep thanks and gratitude to all of you who have supported the journal over the past 6 years, i.e., the period when Acta continued without a JIF. Particular thanks go to our Editorial Board, Guest Editors, and contributors to special issues, peer reviewers, and naturally to our committed authors who never lost their faith in Acta Cytologica. Many of you who have not been able to contribute in those ways still took the time to sign an online petition for the return of the JIF in 2017, in which an incredible number of over 1,000 signatures were collected. Your help in this project was invaluable and we thank you for your support!

First, we expect to see an increasing number of submissions – particularly from authors working in countries or institutions that place great weight on the JIF. We warmly welcome these submissions. In particular, we would like to receive high-quality original papers, meta-analyses, comprehensive reviews, technical innovations, and particularly interesting case reports (with a comprehensive literature review). In this respect, the priorities in the publication policy of Acta Cytologica have not significantly changed [4].

Second, we will introduce sections on events and news from the International Academy of Cytology (IAC) and affiliated national societies. During this time of -COVID-19, it is more important than ever to have a central reference point for our community. Being the official journal of the IAC, Acta Cytologica is a truly unique and global cytological journal reaching different regions of the world – even those that in the past had less access to the medical literature. For the last 60+ years, a printed copy of Acta Cytologica has been on the coffee table of pathology laboratories across the world – this will not change!

Kari Syrjänen, Editor-in-Chief

Fernando Schmitt, General Secretary IAC

1.
Syrjänen
 
K
,
Vielh
 
P
,
Schmitt
 
F
,
Nold
 
T
.
Editorial
.
Acta Cytol
.
2015
;
59
(
1
):
1
.
https://doi.org/10.1159/000375267
[PubMed]
0001-5547
Google Scholar
Crossref
Search ADS
PubMed
 
2.
Publisher’s Note
.
Publisher’s Note
.
Acta Cytol
.
2017
;
61
(
4-5
):
257
–
8
.
https://doi.org/10.1159/000475110
0001-5547
Crossref
Search ADS
 
3.
Publisher’s Note
.
Publisher’s Note
.
Acta Cytol
.
2018
;
62
(
5-6
):
317
–
317
.
https://doi.org/10.1159/000494865
0001-5547
Crossref
Search ADS
 
4.
Syrjänen
 
K
.
Keynotes from the new editor-in-chief
.
Acta Cytol
.
2013
;
57
(
6
):
543
–
4
.
https://doi.org/10.1159/000356294
0001-5547
Google Scholar
Crossref
Search ADS
 
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.